Publication

1. Targeting bacitracin resistance-associated histidine kinase (BraS) in MRSA with isatin and indazole derivatives. Sci Rep(2026). https://doi.org/10.1038/s41598-026-49362-w [IF: 3.9]
2. MPXV protein scaffold cum antigen-based macromolecular multi-antigen displaying next-generation vaccine, providing coordinated humoral and cellular response. International Journal of Biological Macromolecules 2026 Feb:347:150733., [IF: 8.5]
3. SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo. Front Immunol. 2026 Jan 15;16:1724625. [IF: 5.9]
4. Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2. iScience. 2025 Sep 4;28(10):113498. [IF: 4.1]
5. Arabidopsis GELP53 overexpression modulates polysaccharide acetylation and defense through oligosaccharide-mediated signaling. Plant Cell. 2025 Oct 31;37(11):koaf184.[IF: 12.085]
6. A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concerns. PLOS Pathogens; 2022 Dec 12;18(12):e1010994[IF: 5.5]
7. Proinflammatory innate cytokines and metabolomic signatures predict T cell response in active COVID-19. Vaccines (Basel). 2022 Oct; 10(10): 1762.;[IF: 5.2]
8. Virus-like particles of SARS-CoV-2 as virus surrogates: morphology, immunogenicity, and internalization in neuronal cells. ACS Infectious Diseases; 2022 Sep 21 : acsinfecdis.2c00217[IF: 5.084]
9. Dietary αKG inhibits SARS CoV-2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt, Clinical and Translational Medicine; 2022 Sep;12(9):e1041. doi: 10.1002/ctm2.1041.[IF: 10.6]
10. Characterization of broadly cross reactive tetravalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS CoV-2., 3 Biotech; 2022 Sep;12(9):202. doi: 10.1007/s13205-022-03272-6[IF: 2.6]
11. Generation of soluble, cleaved, well-ordered, native-like dimers of Dengue virus 4 envelope protein suitable for vaccine immunogen design. International Journal of Biological Macromolecules; 2022 Sep 30;217:19-26. doi: 10.1016/j.ijbiomac.2022.07.028. Epub 2022 Jul 9[IF: 7.7]
12. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARSCoV-2 and variants of concern. Nature Microbiology, 2022 Jun 9. doi: 10.1038/s41564-022-01161-5.[IF:20.5]
13. Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV2 infection. elife. 2022 Jan 11;11:e73522. doi: 10.7554/eLife.73522.[IF:6.4]
14. The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41. International Immunopharmacology, 101, B, Dec 2021, 108187 [IF:4.8]
15. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2021 Nov 25;S1473-3099(21)00680-0 [IF:36.4]
16. Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus. International Immunopharmacology. 2021 Oct;99:108020(Co-First Author) [IF:4.8]
17. A novel G-quadruplex aptamer-based spike trimeric antigen test for the detection of SARS-CoV-2. Mol Ther Nucleic Acids. 2021 Jun 24;26:321-332. doi: 10.1016/j.omtn.2021.06.014.[IF:6.5]
18. Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. Frontiers in Immunology 24 May 2021, https: //doi.org/ 10.3389/ fimmu.2021.641447(first and corresponding author) [IF:7.561]
19. Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study. American Journal of Tropical Medicine and Hygiene, 2021 May 18; tpmd210164. doi: 10.4269. [IF:3.707]
20. SARS-CoV2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses In vivo and Inhibit Viral Replication In vitro. Frontiers in Immunology, 2021 Mar 26;12:613045. doi: 10.3389/fimmu.2021.613045. [IF:7.561]
21. A novel rapid strategy for production, purification, and functional characterization of single-chain variable antibody fragments (scFvs) containing amber stop codons. Biotechnology Progress, 2021 Feb 23;e3136. doi: 10.1002/btpr.3136[IF:2.478]
22. Development of a fast SARS-CoV-2 IgG ELISA, based on receptor-binding domain, and its comparative evaluation using temporally segregated samples from RT-PCR positive individuals. Frontiers Microbiology.DOI: 10.3389/fmicb.2020.618097 [IF:4.0]
23. Comparative evaluation of SARS-CoV-2 IgG assays in India. J Clin Virol. 2020 Oct; 131: 104609 [IF:4.0]
24. Design and characterization of a germ-line targeting soluble, native-like, trimeric HIV-1 Env lacking key glycans from the V1V2-loop. Biochimica et Biophysica Acta, 2021 Jan;1865(1):129733. doi: 10.1016/j.bbagen.2020.129733[IF:4.0]
25. Tetramerizing tGCN4 Domain Facilitates Production of Influenza A H1N1 M2e Higher Order Soluble Oligomers that Show Enhanced Immunogenicity In vivo. J Biol Chem, 2020 Oct 16;295(42):14352-14366. doi: 10.1074/jbc.RA120.013233.[IF:4.0]
26. Identification of an anti-SARS-CoV-2 receptor binding domain directed human monoclonal antibody from a naïve semi-synthetic library. J Biol Chem, 2020 Jul 29;jbc.AC120.014918.  doi: 10.1074/jbc.AC120.014918. [IF:4.0]
27. HIVR4P 2018: From Research to Impact Conference Summary and Highlights. AIDS Res Hum Retroviruses.2019 May 29. doi: 10.1089/AID.2019.0074 [IF: 1.5]
28. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response. Vaccines, 2018 Mar 14; 36 (12):1627-1636. (First Author) [IF: 4.5]
29. Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail.Retrovirology2018 Jul 20:15 (1):50 [IF: 2.7]
30. Characterization of a stable HIV-1 B/C recombinant, soluble and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. Journal of Biological Chemistry, 2017 Sep 22; 292(38): 15849–15858. [IF: 4.0]
31. Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. Virology, 2017 Oct; 51: 22-28.[IF: 2.8]
32. Stabilization of a soluble, native-like trimeric Env of an efficiently cleaved Indian HIV-1 clade C. Journal of Biological Chemistry, 2017 May 19;292 (20):8236-8243.  [IF:4.0]
33. Association of mutations in V3C3 domain with shift in evasion of HIV-1 clade C from follow up broadly neutralizing contemporaneous plasma antibodies in an elite neutralizer. Retrovirology, 2016; 13: 41. [IF: 2.7]
34. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in V1 Loop. Journal of Virology. 2016 Jan 13. pii: JVI.03090-15, [IF: 4.0]
35. An efficiently cleaved and native-conformation HIV-1 clade C Env that selectively binds to neutralizing antibodies. PLoS One, 2015 Mar 30; 10(3):e0122443. doi: 10.1371/journal.pone.0122443. [IF: 2.9]
36. Structural basis of Ets1 activation by Runx1. Nature - Leukemia, 2014 Oct; 28(10):2040-8. (First Author) [IF: 12.8]
37. Ligand-Induced Structural Transitions, Mutational Analysis, and ‘Open’ Quaternary Structure of the M. tuberculosis Feast/Famine Regulatory Protein (Rv3291c). Journal of Molecular Biology, 2009, 392, 1007–1019. (First Author) [IF: 4.7]
38. Mechanistic insights from the crystal structures of a feast/famine regulatory protein from Mycobacterium tuberculosis H37Rv. Nucleic Acid Research, 2007, 35 (21): 7324-35. (First Author) [IF: 16.97]
39. Cloning, expression, purification and crystallization of a transcriptional regulatory protein (Rv3291c) from Mycobacterium tuberculosis H37Rv. Acta Crystallographica Sect D, 2004, D 60, 1874 – 76 (First Author) [IF: 7.652]
40. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Applied Microbiology and Biotechnology, 2021; 105(16-17): 6315–6332. [IF: 3.9]
41. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. International Immunopharmacology, Volume 85, August 2020, 106639. [IF: 4.8]
42. Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.Applied Microbiology and Biotechnology. 2020 Apr;104(8):3209-3228. [IF: 3.9]
43. Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies. International Journal of Biological Macromolecule. 2019 Jun 3. pii: S0141-8130(19)33085-5. Review [IF: 7.7]
44. Three-Dimensional Structures of DNA-Bound Transcriptional Regulators.Methods Mol Biol. 2010; 674:43-55, Review (First author) [IF.0.788]
45.  

• Shuja S. Malik and Tripti Shrivastava. Protein characterization using modern biophysical techniques. Advances in Protein Chemistry, OMICS Group Incorporation

1. Indian Patent Application no. 202511084114. Title:Epitope focused vaccine candidate (s) of RSV; a vaccine development platform, its method and uses thereof. Tripti Shrivastava, Rakesh Chaudhary, Ankit Gupta, Puneet Srivastav
2. Indian Patent Application: 202411069393. Title: MONKEY POX E2 PROTEIN BASED SCAFFOLD CUM VACCINE ANTIGEN, DERIVED VACCINE CANDIDATES AND ITS METHODS AND USES THEREOF, Tripti Shrivastava, Ankit Gupta, Priyasi Mittal, Rakesh Chaudhary, Puneet Srivastav.
3. Indian Patent Application: 202411031526. Title: A CHIKV sE1-sE2-E3 subunit vaccine and method thereof, Supratik Das, Anica Dadwal, Tanvi Agrawal, Amit Awasthi, Akshay Binayke, Tripti Shrivastava, Puneet Srivastav
4. PCT Application PCT/IN2024/052016, LIPC Ref.: PCT0049, Title: A UNIVERSAL INFLUENZA VACCINE CANDIDATE AND ITS USES THEREOF, Tripti Shrivastava, Puneet SRIVASTVA,
5. Indian Patent Application No.: 202211065678, Title: HA MONOMER BASED UNIVERSAL INFLUENZA VACCINE CANDIDATE AND ITS USES THEREOF, Tripti Shrivastava
6. Indian Patent Application No.: 202111036849 (Granted). Title:RECOMBINANT CONSTRUCT, IMMUNOGENIC COMPOSITION AGAINST DENGUE VIRUS AND IMPLEMENTATION THEREOF, Chandrasekhar Kumar, Tripti Shrivastava, Manidipa Banerjee, Hilal Ahmed Parray, Adarsh Kumar Chiranjivi, Supratik Das, Shubbir Ahmed, Rajesh Kumar
7. Indian Patent Application No.: 202021015307. Title: DNA CONSTRUCT EXPRESSING RECEPTOR BINDING DOMAIN OF SARS-COV-2 PROTEIN, THE PROCESS TO PRODUCE THE SAME AND ITS USES THERE OF, Dr Tripti Shrivastava, Sandeep Goswami
8. Indian Patent Application No.: 20191 1027069. Title: A H1N1 Influenza virus M2e ectodomain protein obtained from an arrangement of M2e ectodomain polypeptides and uses thereof, Dr. Sweety Samal, Dr . Rajesh Kumar, Dr . Tripti Shrivastava, Naresh Kumar, Manish Bansal
9. International Application No.: PCT/US2015/057098, Pub. No.: WO/2016/065252. Title:NATIVE TRIMERIC ENV IMMUNOGEN DESIGN, Bimal  Chakrabarti,  Saikat  Boliar,  Supratik  Das,  Tripti  Shrivastava,  Richte  Charles  King,  Jayanta  Bhattacharya, Sweety Samal

1. National One Health Mission (NOHM) Grant on Chandipura virus Vaccine candidate development, PI, 2026-2029
2. DBT: Identification of novel and potent growth-inhibiting plasma-proteins (Co-PI), DBT, 2024-2026.
3. AIIMS-THSTI Collaborative project on Respiratory viruses
4. THSTI Intramural Grant (P543): Development of vaccine candidate for Chandipura Virus (2024-2026)

2022 WHO, Geneva, nominee from India to attend Scientific blue print to deal with disease X, sponsored by WHO, Geneva

2022   Dr M. K. Bhan group award for most impactful collaboration award

2021   Dr M. K. Bhan group award for most impactful collaboration award

2020   Best poster Awards by VIROCON 2020, INSA, India

2018   Travel Award and full Scholarship for HIV R4P 2018, Madrid, Spain

2018   Awarded as Rapporteur for HIV R4P 2018 conference at Madrid, Spain

2018   Nomination for Young Scientist Conference- IISF 2018, Lucknow, 5th October to 8th October, 2018

2018   Invitation for DBT- sponsored brain storming meeting CIIDRET-UDSC on 14th December, 2018

2018 Nomination for the DBT-BioCARe conclave: Women Scientists Achieving Great Heights" 8-9th March,2019

2016   Travel Award and full Scholarship for HIV R4P 2016, Chicago, USA

2008   “Dr D. L. Shrivastava” Young Scientist Award, Society of Biological Chemistry, India.

2007   Best Publication Award, Central Drug Research Institute, Lucknow, India

PDB DEPOSITION

• 2IVM- Crystal structure of a transcriptional regulator
• 2VC1, 2VC0, 2VBZ, 2VBY, 2VBX, 2VBW, 2W24 - Feast or famine regulatory protein (Rv3291c) from M. Tuberculosis complexed with amino acids
• 2W25, 2W29 - Crystal structure of mutant Protein (Glu104Ala and Gly102Thr)
• 4L0Y, 4L0Z, 4L18- Crystal structure of Runx1 and Ets1 bound to TCR alpha promoter (crystal form 1, 2 & 3) 

MEMBERSHIP OF PROFESSIONAL ORGANIZATION

• Life Member of Indian Crystallographic Association (ICA) (LM 609)
• Life Member of Indian Virological Society (LM-242/IVS/2020)
• Life Member of Indian Immunology Society (844/01/20)

1. Dr Ankit Gupta: Project Research Scientist - I

2. Rakesh Chaudhary, PhD Student

3. Puneet Kumar Srivastva, PhD Student

4. Sarvesh Kumar, project Assistant

5. Ajay Kumar, Project technical Assistant -II